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Simpson-Golabi-Behmel syndrome (SGBS) is a rare overgrowth syndrome clinically characterized by multiple
congenital abnormalities, pre/postnatal overgrowth, distinctive craniofacial features, macrocephaly, and organomegaly.
Abnormalities of the skeletal system, heart, central nervous system, kidney, and gastrointestinal tract may also be
observed. Intellectual disability, early motor milestones and speech delay are sometimes present; however, there are a
considerable number of individuals with normal intelligence.
Genomic rearrangements and point mutations involving the glypican-3 gene (GPC3) at Xq26 have been shown to
be associated with SGBS. Occasionally, these rearrangements also include the glypican-4 gene (GPC4). Glypicans are
heparan sulfate proteoglycans which have a role in the control of cell growth and cell division.
Although a lethal and infrequent form (also known as SGBS type II) has been described, only the classical form of SGBS
is reviewed in this work, whereas only some specific features on SGBS type II are commented.
We review all clinical and molecular aspects of this rare disorder, updating many topics and suggest a follow-up
scheme for geneticists and primary care clinicians.
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El Síndrome de Simpson-Golabi-Behmel (SSGB) es un síndrome de sobrecrecimiento raro, que se caracteriza
clínicamente por múltiples anomalías congénitas, sobrecrecimiento pre y post natal, rasgos craneofaciales
distintivos, macrocefalia y organomegalia. Otras características que pueden presentar estos pacientes incluyen
anomalías en el aparato esquelético, el corazón, el sistema nervioso central, el riñón y el tracto gastrointestinal.
También pueden presentar discapacidad intelectual, retraso motor precoz y retraso en el habla, aunque en su
mayoría, estos individuos presentan una inteligencia dentro de los límites normales.
Los reordenamientos genómicos y las mutaciones puntuales que incluyen el gen GPC3 (“Glypican-3 gene”)
localizado en la región cromosómica Xq26, se han asociado con la aparición del SSGB. Ocasionalmente, estos
reordenamientos genómicos pueden incluir el gen GPC4. Los glipicanos son proteoglicanos de heparán sulfato
que actúan controlando el crecimiento y división celular.
Aunque se ha descrito una forma letal de este síndrome (denominada SSGB tipo II) en esta revisión sólo analizamos la
forma clásica de este síndrome y sólo comentaremos algunos aspectos del SSGB tipo II.
En este trabajo se presenta una revisión de todos los aspectos clínicos y moleculares de este síndrome, actualizando
algunos aspectos y además se sugiere un esquema de seguimiento de estos pacientes por parte de genetistas y
médicos de atención primaria.* Correspondence: pablo.lapunzina@salud.madrid.org
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The Simpson-Golabi-Behmel syndrome (SGBS) (OMIM
312870;ORPHA373) is an overgrowth/multiple congenital
anomalies syndrome caused by mutations in a semi-
dominant X-linked gene encoding Glypican 3 (GPC3). It
shows high clinical variability (Table 1), ranging from very
mild forms in carrier females to lethal forms with failure
to thrive in males. The most consistent findings in SGBS
are pre- and postnatal overgrowth, characteristic facial
anomalies and abnormalities affecting the internal organs,
skeleton, and in some occasions, variable degree of intel-
lectual disability. SGBS is also associated with an increased
risk of developing embryonal tumors (Table 1), mostly
Wilms and liver tumors. About 250 patients have been
reported so far in the medical literature. The prevalence of
the syndrome is unknown.
To date, two different clinical subtypes of SGBS have
been described. The classical SBGS (also known as SGBS
type I) [1-4] and a lethal and infrequent form (probably
with less than 10 cases described; also known as SGBS
type II. OMIM 300209; ORPHA79022) described by
Terespolsky et al., in 1995 [5,6].
In this work we review all aspects of the classical form
of SGBS. Due to the scant number of patients reported
with SGBS type II, only some minimal aspects of this
disorder are commented in this manuscript.Disease definition
SGBS was initially described by Joe Leigh Simpson and
coworkers in 1975 [1]. In 1984, Golabi and Rosen [3]
and Behmel et al. [2] independently reported further
cases. Neri et al. [4] described additional cases, put all
these reports together and named the disorder “Simpson-
Golabi-Behmel syndrome”. The old terms “Golabi-Rosen
syndrome”, “Gigantism-dysplasia syndrome”, “Encephalo-
tropho-schisis syndrome” and “Simpson dysmorphia
syndrome” and the pejorative “Bulldog syndrome” are
no longer in use for SGBS and should be avoided.Epidemiology
SGBS syndrome is a rare overgrowth disorder, less com-
mon than the Beckwith-Wiedemann and Sotos syndromes.
The birth prevalence is unknown. Approximately 250 cases
are known to date.Clinical description
There are at least two different clinical subtypes of SGBS.
The classical form (SGBS or SGBS type I) associated to
mutations in GPC3 and a lethal form (SGBS type II)
associated to a different region of chromosome X (Xp22.2)
[5]. The lethal form is an infantile lethal variant of SGBS
usually associated with hydrops fetalis.Clinical findings
Clinical subtypes of SGBS
There are two different clinical subtypes of SGBS. The
classical SBGS (also known as SGBS type I) [1-4] and a
lethal and very infrequent form (known as SGBS type II.
OMIM 300209; ORPHA79022) described by Terespolsky
et al., in 1995 [5,6]. Clinical findings below correspond
mainly to those features observed in classical SGBS type
I. Due to the phenomenon of Lyonization; some female
carriers may have mild physical findings of SGBS. Some
carrier women are tall, have extranumerary nipples,
coarse face, abnormal hands and midline defects.Skull
Macrocephaly is observed in about 70% of children
with SGBS. Craniosynostosis has been reported in many
cases [7,8].Face
The face in patients with SGBS is square and coarse. The
forehead is large and the nose and lips are usually large and
thick. Cleft lip and/or palate is observed in about 13% of
cases. The tongue is wide and with a middle groove from
the tip to the back of the tongue [9-11] (Figure 1). There
may be midline minor anomalies such as subcutaneous
lipomas, pits or flat nevus flammeus. Multiple odontogenic
keratocysts were reported in one patient [12].Neck
Laryngeal web [13] and airway and swallow manifestations
were reported in a minority of children [14].Heart
Diverse cardiovascular malformations have been reported
in patients with SGBS, and it is suspected that they are
related to the apparently high incidence of early death
[15]. Lin et al. [15] reviewed 101 SGBS patients and
demonstrated that 36% had a cardiac abnormality, of
which 26 had a cardiovascular malformation. Most cases
(77%) were class II CVMs (attributed to altered embryonic
intracardiac flow). Other cardiac abnormalities included
cardiomyopathy (n = 4) and electrocardiogram (ECG) con-
duction or rhythm abnormalities. Death was associated
with a cardiac abnormality in 23% of patients. The authors
conclude that cardiac abnormalities of any type are com-
mon in SGBS [15].Vascular findings
Carotid artery dissection in an adult [16], hepatic vascu-
lar malformations [17] and diffuse neonatal hemangioma-
tosis has been associated with SGBS [18].
Table 1 Clinical findings in Simpson-Golabi-Behmel
Syndrome Type I (SGBS Type I)
1. Craniofacial features
Skull Macrocephaly in 70% of children.
Craniosynostosis is observed in
many of the cases
Face Square and coarse. Large forehead.
Cleft lip or palate in 13% of the patients.
Wide and middle groove tongue
Nose and lips large and thick
Palate Cleft palate is present in about 13%
of the patients
Tongue Wide and middle groove from the tip
to the back
2. Tumors
Tumor risk Wilms tumor, hepatoblastoma, adrenal
neuroblastoma, gonadoblastoma and
hepatocellular carcinoma has been
described in patients with SGBS
3. Cardiovascular abnormalities
Cardiac abnormalities Any type of cardiac abnormalities are
very common in SGBS
Cardiovascular malformations Altered embryonic intracardiac flow
Cardiomyopathy In about 4% of the cases
Conduction or rhythm
abnormalities
In a low percentage of patients
Carotid artery dissection One case has been described
ECG abnormalities In about 12% of the patients
4. Abdominal region
Visceromegaly Nephromegaly, splenomegaly
and hepatomegaly is common
Congenital Diaphragmatic
Hernia (CDH)
Was observed in less than 10%
of the cases reported
Neonatal liver disease One patient has been described. Finally
developed early biliary cirrhosis
Choledochal cyst,
biliary cirrhosis
Only reported in 1 patient
5. Genitalia
Hypospadias These three features have been reported





Proximal phalanx Congenital abnormality
Syndactyly 2nd-3rd finger
Rib malformations Frequent
Sella turcica Deep V-shaped
Six lumbar vertebrae Exceptional





Table 1 Clinical findings in Simpson-Golabi-Behmel
Syndrome Type I (SGBS Type I) (Continued)
Attention deficit hyperactivity
disorder
8. Speech and language





Neck Laryngeal web and airway swallow
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Data are insufficient to define a cardiac phenotype/mo-
lecular correlation [15]. Lin et al. [15] reviewed 101 cases
and reported that 12% of cases had ECG abnormalities,
25% of whom had an underlying cardiovascular malforma-
tion. Out of the 29 deaths in Lin and coworkers’ review
[15], 9 (31%) were associated with a structural cardiac
abnormality, and only one was associated with an ECG
abnormality (partial right bundle branch block). Although
previous reports indicate neonatal mortality in affected
males with SGBS to be as high as 50% [4], there is no clear
evidence that arrhythmias have the major role in neonatal
mortality without the presence of a major cardiac malfor-
mation. There are sufficient data to recommend a baseline
echocardiogram and ECG in SGBS patients.
Thorax
Besides cardiovascular anomalies, supernumerary nipples
are common in both affected individuals and carrier
females (Figure 1).
Abdominal region
Visceromegaly (nephromegaly, splenomegaly and hepato-
megaly) is quite common. Congenital diaphragmatic
hernia (CDH) [19] is observed in less than 10% of children.
Neonatal liver disease leading to an early biliary cirrhosis
has been reported in one individual who finally needed liver
transplantation [20]. Choledochal cyst is also reported in
one patient [21].
Genitalia
Hypospadias, cryptorchidism and penoscrotal transpos-
ition have been observed in some individuals [22]. In
one patient cryptorchidism also associated chordee of
the penis (Figure 1).
Intellectual disability
Intellectual disability may be present in this disorder.
Patients must be carefully evaluated because most of
them may have normal intelligence instead of the
coarse facial features and difficulties in speech.
Figure 1 Clinical findings in Simpson-Golabi-Behmel syndrome. A and B: Facial phenotype. Note the cleft lip, coarse, square face and broad
nose. C and D: extra-nipple in a carrier mother and a toddler. E, F and G: close up of the mouth of three different patients. Note the large tongue,
middle groove in the tongue, teeth malposition and repaired cleft (in G). H and J: Hands. Note broad hands and polydactyly in one subject. I: Deep
plantar creases. K: abnormal genitalia in a male with hypospadias and proximal anal placement. Written informed consent was obtained from the
parents of the patients for publication of their photographs.
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Speech was characterized by a distorted articulation, distorted
resonance, fluency failures, and stereotype prosody [23].
Skeletal
Marked index finger hypoplasia and a congenital abnormal-
ity of the proximal phalanx [24] and of the same fingernail,
and 2nd-3rd finger syndactyly [25] is observed in many
patients. Polydactyly (postaxial) may be found in a minority
of individuals (Figure 1). Other skeletal findings include rib
malformations, deep V-shaped sella turcica and six lumbar
vertebrae [26].
CNS
Generalized hypotonia is one of the main clinical findings
in SGBS. Hydrocephalus, epilepsy [27], obstructive sleep
apnea syndrome [28] and attention deficit hyperactivity
disorder may be present [29].
Genotype-phenotype correlations
There is no genotype-phenotype correlation. In a study
of genotype-phenotype correlations, Mariani et al. [30]
determined that all deletions and point mutations occur-
ring in the eight GPC3 exons result in loss of function
with no phenotypic distinctions based on size or position
of a deletion or point mutation [31].
Penetrance
The penetrance is 100%; all males with a GPC3 mutation
have had clinical findings of SGBS. Penetrance in hetero-
zygous females is not known.
Tumor risks and tumor predisposition
Affected individuals with SGBS are at increased risk for
embryonal tumors, including Wilms tumor, hepatoblastoma,adrenal neuroblastoma, gonadoblastoma, and hepatocellular
carcinoma. A review of the main tumors (Wilms, gonado-
blastoma, neuroblastoma and liver tumors) observed in
SGBS patients have been reported in 2005 [32]. Kosaki et al.
[33] reported a SGBS patient with hepatoblastoma and a
CTNNB1 somatic mutation (p.Ile35Ser) together with a
germline loss-of function mutation in GPC3. Since the
CTNNB1 mutation in the tumor tissue represents a driver
mutation, these data suggest that mutation in GPC3 may
influence one of the initial steps in tumorigenesis and the
progression to hepatoblastoma. Other patients with SGBS
and hepatoblastoma [33,34] both at age 9 months, [35]
and at 14 months have been also described. Hepatocarci-
noma is less common [11]. Metastatic medulloblastoma in
an adolescent has been published [36].
Etiology
SGBS type I
After the mapping efforts done for some groups [37] a
translocation [38] in a woman with an X-autosome trans-
location led to the recognition of GPC3 as the gene
responsible of the disease. Most cases follow an X-linked
inheritance though some cases are de novo. There is at
least one family with germinal mosaicism [39]. Deletions,
duplications and point mutations of GPC3 have been
reported in patients with SGBS type I. There is only one
report of a duplication of GPC4 [40]; thus, the role of this
gene in the pathogenesis of SGBS type I needs further
investigations and evidences. No point mutations of GPC4
were reported so far in individuals with SGBS type I.
SGBS type II
There are a small number of reports on this rare form of
the disease [5,6,41]. It is an infantile lethal variant of
SGBS associated with hydrops fetalis. In the first report,
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with a severe variant of SGBS [6]. One of these males
was aborted therapeutically at 19 weeks of gestation
following the detection of multicystic kidneys on ultra-
sound. The three live born males were hydropic at
birth. They also depicted craniofacial anomalies including
macrocephaly; apparently low-set, posteriorly angulated
ears; hypertelorism; short, broad nose with anteverted
nares; large mouth with thin upper vermilion border;
prominent philtrum; high-arched and cleft palate. Other
findings were short neck; redundant skin; hypoplastic
nails; skeletal defects involving upper and lower limbs;
gastrointestinal and genitourinary anomalies, hypotonia
and neurologic impairment. All patients died within the
first 8 weeks of life. SGBS type II maps to Xp22 and is
postulated to be a distinct disorder with overlapping
phenotypic features. Budny et al. [41] identified a CXORF5
(also called as OFD1) mutation in one family with some
clinical findings suggestive of SGBS type II but further
analysis of 17 patients with clear phenotypic features of
SGBS and negative for GPC3 mutations found no muta-
tions in CXORF5 [42]. Thus, CXORF5 is not clearly asso-
ciated to SGBS type II.
The gene and proteins in the pathway
Glypicans (GPCs) are a family of proteoglycans that are
bound to the cell surface by a glycosylphosphatidyli-
nositol anchor. Six glypicans have been found in the
mammalian genome (GPC1 to GPC6). GPCs regulate
several signaling pathways [43]. Given the critical role
that insulin-like-growth factor II (IGF-II) plays in the
regulation of embryonic growth, it was initially proposed
that GPC3 was an inhibitor of IGF-II, and that the
overgrowth observed in the SGBS patients was due to
an increase in IGF-II signaling caused by the loss of
functional GPC3. However, GPC3 does not interact
with IGF-II, GPC3-null embryos display normal levels
of IGF-II [43-45] and the fact that the crossing of the
GPC3-null mice with various mouse strains that lacked
critical components of the IGF signaling pathway did
not show any genetic interaction [46] gave a definitive
proof that overgrowth in SGBS patients is independent
of IGF. Capurro et al. hypothesized that GPC3 acts as
an inhibitor of Hedgehog (Hh) signaling in the embryo,
and that the overgrowth found in SGBS patients is
due, at least in part, to hyperactivation of hedgehog
signaling caused by the loss of functional GPC3, which
was demonstrated by the finding that hedgehog signal-
ing activity is elevated in GPC3-null mice [47]. The
binding of Hh to GPC3 triggers the endocytosis and
degradation of the GPC3/Hh complex [47]. Additional
evidence that GPC3 is a negative regulator of Hhsignaling
was recently provided by some experiments performed in
cultured Drosophila cells [43,48].Diagnosis
Diagnostic criteria
The major diagnostic criteria are: overgrowth (macroso-
mia, macrocephaly and/or pre-and postnatal overgrowth),
coarse, characteristic facial appearance, midline defects
and tumor predisposition (Table 1). Other findings are
organomegaly, anomalies of the skeletal system, and
congenital malformations of the heart, central nervous
system, kidney, and gastrointestinal tract. Intellectual
disability of variable degree may be present.
Diagnostic methods
Diagnosis is suspected on the clinical findings, pedigree
analysis and medical problems of patients. Genetic
approach currently includes a karyotype focusing on the X
chromosome, array CGH and/or MLPA analysis and
mutation analysis of the GPC3/GPC4. Next generation
sequencing technologies have allowed the simultaneous
testing of many genes responsible of overgrowth through
panels of genes or directly through whole exome sequen-
cing [49].
Laboratory and medical imaging findings
No biochemical or endocrinological pathognomonic
markers have been documented in patients with SGBS.
Central nervous system findings on CT scan or brain
MRI are common; midline defect such as abnormal
corpus callosum, central lipomata, and hydrocephalus
may be present. On X-rays are very useful a typical sign of
index finger hypoplasia and a congenital abnormality of
the proximal phalanx [24] and of the same fingernail. Rib
malformations are usually observed in most patients.
Differential diagnosis
SGBS belongs to a group of overgrowth syndromes that
have some clinical features in common such as pre- and/
or postnatal overgrowth and in some of them cancer pre-
disposition. SGBS syndrome has clinical overlap with
other overgrowth syndromes, in particular with Beckwith-
Wiedemann syndrome. Beckwith-Wiedemann syndrome
due to CDKN1C mutations demonstrates the highest
clinical similarities with SGBS, including genitourinary
malformations, an increased incidence of embryonic
tumors, macrosomia, macroglossia, coarse face and ear
anomalies. However, the mode of inheritance of SGBS
may help to differentiate these disorders. Other entities
that should be considered in the general differential diag-
nosis of SGBS syndrome are: Weaver syndrome, Perlman
syndrome; Fragile X syndrome; Bannayan-Zonana syn-
drome; PTEN hamartoma tumor syndrome; Marshall
syndrome, Nevo syndrome; Neurofibromatosis type I;
Marfan syndrome; nevoid basal cell carcinoma syndrome
(Gorlin syndrome), Fryns syndrome, Elejalde syndrome
(acrocephalopolydactylous dysplasia), mosaic trisomy 8,
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SGBS is inherited in an X-linked fashion. If there is only
one affected individual in a family, the patient may have
inherited the mutation from his mother or may have a
de novo mutation. Reviewing all published cases of SGBS
indicates that the frequency of de novo mutations is
about 20-30%. In families with more than one affected
individual, the mother of an affected male may be a car-
rier (most probably) or may have germline mosaicism
(rarely). Chromosome analysis (including FISH) and
aCGH/MLPA of the mother needs to be performed when
a deletion of GPC3 is detected in the affected child.
Molecular tests looking for point mutations through
sequencing methods (Sanger, NGS, etc.) should be war-
ranted for every mother of molecularly-confirmed indi-
vidual. Germline mosaicism is extremely rare and has
been reported in only one family [39].
Sibs
The risks of brothers and sisters of a patient will depend
on the status of the mother. If the mother of a patient is
carrier of the molecular defect, the probability of trans-
mitting the disease in each pregnancy is 50%. Brothers
who inherit the mutation will be affected by the disorder
and sisters who inherit the mutation will be carriers and
will usually not be affected or show minimal clinical
findings of SGBS [50].
Offspring
Male SGBS patients will transmit the GPC3 mutation to
all of their daughters and none of their sons that will not
be affected by the disease. Daughters of affected male
patients will be carriers.
Antenatal diagnosis and preimplantational genetic testing
Ultrasound examination
Ultrasound approach is possible in families at risk of
SGBS [50-52]. Increased nuchal translucency and other
ultrasound findings such as macrosomia, cleft lip or palate,
nephromegaly, macroglossia and hydrops/ascites may sug-
gest the fetus is affected [7,53]. The finding of dispropor-
tionate fetal overgrowth together with elevated maternal
serum alpha-fetoprotein is also useful to suspect SGBS [19].
Molecular tests
Once the mutation has been identified in a patient or any
family member, prenatal diagnosis and/or preimplantational
genetic testing is possible for at-risk pregnancies [50].Management & treatment
General management
It includes treatment of neonatal hypoglycemia and multi-
disciplinary support of many pediatric specialists such
as cardiologist, neurologist, and orthopedist. Specific man-
agement and follow-up of tumors should be warranted to
all individuals with SGBS (see below).
Management for males with SGBS
 Monitoring for hypoglycemia in the newborn period.
 Physical examination to monitor for scoliosis during
period of rapid growth rate; radiographs as needed.
 If development appears to be normal on initial
assessment, routine monitoring of social and
intellectual development.
 Monitoring of renal function if renal anomalies
are present.
 Physical examinations to monitor for tumor risk
[32]: a) Every three months until age four years;
b) Every four months from age four to seven years;
c) Biannually after seven years of age.
Main tumors to be screened are: 1) Wilms and liver
tumors: Abdominal ultrasound examination every three
and four months from birth until at least age seven and
yearly there after [32,54]. Abdominal ultrasound examin-
ation should assess for both Wilms tumor and hepatic
tumors. Similarly to Beckwith-Wiedemann syndrome, the
risk for Wilms tumor seems to decrease after eight years of
age; 2) Gonadoblastoma. Serial measurements of serum
alpha fetoprotein and beta human chorionic gonadotropin
concentrations (also for hepatoblastoma) is recommended
[32]; 3) Neuroblastoma. Measurements of urinary cat-
echolamine metabolites including vanillylmandelic acid and
homovanillic acid as well as urinary free fractionated cate-
cholamines [32] and annual lifelong chest radiograms have
also been suggested for chest tumors [32].
Prognosis
The spectrum of signs and symptoms associated to
SGBS is broad, varying from very mild forms in carrier
females to infantile lethal forms in affected males. A
percentage of affected males die in the newborn period,
some of them probably due to heart defects. Carrier
females and people with milder cases often live into
adulthood. Because of the varying degrees of manifestations
and severity associated with the condition, prediction
of prognosis and life expectancy most likely varies on
an individual basis.
Intellectual disability must be carefully evaluated due
to the majority of patients have normal intelligence, and
do not have the coarse facial and difficulties in speech as
we expected for classical SGBS.
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